Prognostic Value of CYP1A2 (rs2069514 and rs762551) Polymorphisms in COVID-19 Patients
, , , and | Jul 31, 2023
About this article
Article Category: Original Article
Published Online: Jul 31, 2023
Page range: 35 - 42
DOI: https://doi.org/10.2478/bjmg-2023-0005
Keywords
© 2023 I Bozkurt et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Distributions of CYP1A2 rs2069514 and rs762551 polymorphisms by ICU and Mortality Status
| Genotype n (%) | AA | 2 (5.7) | 4 (16.0) | 3 (6.4) | 3 (23.1) | |
| AG | 3 (8.6) | 11 (44.0) | 7 (14.9) | 7 (53.8) | ||
| GG | 30 (85.7) | 10 (40.0) | 37 (78.7) | 3 (23.1) | ||
| Allele frequency, n (%) | A | 11 (14.8) | 19 (38.0) | 13 (13.8) | 13 (50.0) | |
| G | 63 (85.2) | 31 (62.0) | 81 (86.2) | 13 (50.0) | ||
| Genotype n (%) | AA | 16 (45.7) | 5 (20.0) | 18 (38.3) | 3 (23.1) | |
| AC | 10 (28.6) | 5 (20.0) | 12 (25.5) | 3 (23.1) | ||
| CC | 9 (25.7) | 15 (60.0) | 17 (36.2) | 7 (53.8) | ||
| Allele frequency, n (%) | A | 42 (59.9) | 15 (30,0) | 48 (51.1) | 9 (34.6) | |
| C | 28 (40.1) | 35 (70.0) | 46 (48.9) | 17 (65.4) | ||
Distribution of age, gender, additional disease, and symptom information of patients with COVID-19 (n=60)
| <65 | 29 (48.3) | |
| ≥65 | 31 (51.7) | |
| Male | 32 (53.3) | |
| Female | 28 (46.7) | |
| No | 38 (63.3) | |
| Yes | 22 (36.7) | |
| No | 47 (78.3) | |
| Yes | 13 (21.7) | |
| No | 39 (65.0) | |
| Yes | 21 (35.0) | |
| No | 54 (90.0) | |
| Yes | 6 (10.0) | |
| No | 50 (83.3) | |
| Yes | 10 (16.7) | |
| No | 33 (55.0) | |
| Yes | 27 (45.0) | |
| No | 37 (61.7) | |
| Yes | 23 (38.3) | |
| No | 50 (83.3) | |
| Yes | 10 (16.7) | |
| No | 59 (98.3) | |
| Yes | 1 (1.7) | |
| No | 56 (93.3) | |
| Yes | 4 (6.7) | |
| No | 45 (75.0) | |
| Yes | 15 (25.0) | |
| No | 60 (100.0) | |
| Yes | 0 (0,0) | |
| No | 40 (66.7) | |
| Yes | 20 (33.3) | |
| Alive | 47 (78.3) | |
| Ex | 13 (21.7) | |
| Alive | 35 (58.3) | |
| Passed away | 25 (41.7) |
Comparison of patients with and without intensive care
| <65 | 5 (17.2) | 24 (82.8) | |
| ≥65 | 20 (64.5) | 11 (35.5) | |
| Male | 15 (60.0) | 17 (48.6) | 0.382 |
| Woman | 10 (40.0) | 18 (51.4) | |
| No | 10 (26.3) | 28 (73.7) | |
| Yes | 15 (68.2) | 7 (31.8) | |
| No | 15 (31.9) | 32 (68.1) | |
| Yes | 10 (76.9) | 3 (23.1) | |
| No | 5 (12.8) | 34 (87.2) | |
| Yes | 20 (95.2) | 1 (4.8) | |
| No | 19 (35.2) | 35 (64.8) | |
| Yes | 6 (100.0) | 0 (0,0) | |
| No | 20 (40.0) | 30 (60.0) | 0.558 |
| Yes | 5 (50.0) | 5 (50.0) | |
| No | 13 (35.1) | 24 (64.9) | 0.193 |
| Yes | 12 (52.2) | 11 (47.8) | |
| No | 10 (30.3) | 23 (69.7) | |
| Yes | 15 (55.6) | 12 (44.4) | |
| No | 25 (50.0) | 25 (50.0) | |
| Yes | 0 (0,0) | 10 (100.0) | |
| No | 24 (40.7) | 35 (59.3) | 0.417 |
| Yes | 1 (100.0) | 0 (0,0) | |
| No | 21 (37.5) | 35 (62.5) | |
| Yes | 4 (100.0) | 0 (0,0) | |
| No | 10 (22.2) | 35 (77.8) | |
| Yes | 15 (100.0) | 0 (0,0) | |
| No | 6 (15.0) | 34 (85.0) | |
| Yes | 19 (95.0) | 1 (5.0) | |
| GG | 10 (25.0) | 30 (75.0) | |
| AA+AG | 15 (75.0) | 5 (25.0) | |
| AA | 5 (23.8) | 16 (76.2) | |
| CC+CA | 20 (51.3) | 19 (48.7) | |
| *1A/*1A | 5 (55.6) | 4 (44.4) | |
| *1A/*1F+*1F/*1F | 5 (16.1) | 26 (83.9) | |
| *1C/*1F | 4 (100.0) | 0 (0,0) | |
| *1A/*1C+*1C/*1C | 11 (68.8) | 5 (31.3) | |
Multivariate Logistic Regression Results on ICU Admission for Various Variables.
| 5.23 (1.22–22.36) | ||
| Chronic disease (ref: none) | 4.68 (1.14–19.15) | |
| Fatigue (ref: none) | 0.92 (0.21–3.94) | 0.920 |
| Age (ref: <65) | 5.17 (1.26–21.14) | |
| R2 =0.48 −2 Log likelihood =55.201 | ||